Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID‐19: Results of a systematic review and meta‐analysis

BACKGROUND: Determining how prior immune checkpoint inhibitor (ICI) therapy influences outcomes in cancer patients presenting with COVID‐19 is essential for patient management but must account for confounding variables. METHODS: We performed a systematic review and meta‐analysis of studies reporting...

Descripción completa

Detalles Bibliográficos
Autores principales: Minkove, Samuel J., Sun, Junfeng, Li, Yan, Cui, Xizhong, Cooper, Diane, Eichacker, Peter Q., Torabi‐Parizi, Parizad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111045/
https://www.ncbi.nlm.nih.gov/pubmed/35416370
http://dx.doi.org/10.1002/rmv.2352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111045/
https://www.ncbi.nlm.nih.gov/pubmed/35416370
http://dx.doi.org/10.1002/rmv.2352

Ejemplares similares